AFLATOXIN B1 IN MOULD EXTRACTS USED FOR DESENSITISATION

Marvin S. Legator; Glenn Kline; V. M. Sadagopa Ramanujam; Bruce R. Cunningham; Jonathan B. Ward; Mohy M. Gad-el Karim

doi:10.1016/S0140-6736(83)90901-7

AFLATOXIN B₁ IN MOULD EXTRACTS USED FOR DESENSITISATION

Marvin S. Legator, Glenn Kline, V. M. Sadagopa Ramanujam, Bruce R. Cunningham, Jonathan B. Ward, Mohy M. Gad-el Karim

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	915
Number of pages	1
Journal	The Lancet
Volume	322
Issue number	8355
DOIs	https://doi.org/10.1016/S0140-6736(83)90901-7
State	Published - Oct 15 1983
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(83)90901-7

Cite this

@article{d1179bcff999409ea9ea8ac2fcb7eb3b,

title = "AFLATOXIN B1 IN MOULD EXTRACTS USED FOR DESENSITISATION",

author = "Legator, {Marvin S.} and Glenn Kline and {Sadagopa Ramanujam}, {V. M.} and Cunningham, {Bruce R.} and Ward, {Jonathan B.} and {Gad-el Karim}, {Mohy M.}",

note = "Funding Information: aflatoxin Bl. Our findings suggest that careful screening of commercially available allergenic mould extracts is warranted. There may be a risk from of iatrogenic aflatoxin-induced illness, 7such as Reye{\textquoteright}s syndrome, 7 hyposensitisation immunotherapy. Based on a report presented at the 14th annual meeting of Environmental Mutagen Society, in San Antonio, Texas, m March, 1983. Supported by the McGregor Allergy Clinic, Houston, Texas. MARVIN S. LEGATOR GLENN KLINE V. M. SADAGOPA RAMANUJAM BRUCE R. CUNNINGHAM JONATHAN B. WARD, JR MOHY M. GAD-EL KARIM",

year = "1983",

month = oct,

day = "15",

doi = "10.1016/S0140-6736(83)90901-7",

language = "English (US)",

volume = "322",

pages = "915",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8355",

}

TY - JOUR

T1 - AFLATOXIN B1 IN MOULD EXTRACTS USED FOR DESENSITISATION

AU - Legator, Marvin S.

AU - Kline, Glenn

AU - Sadagopa Ramanujam, V. M.

AU - Cunningham, Bruce R.

AU - Ward, Jonathan B.

AU - Gad-el Karim, Mohy M.

N1 - Funding Information: aflatoxin Bl. Our findings suggest that careful screening of commercially available allergenic mould extracts is warranted. There may be a risk from of iatrogenic aflatoxin-induced illness, 7such as Reye’s syndrome, 7 hyposensitisation immunotherapy. Based on a report presented at the 14th annual meeting of Environmental Mutagen Society, in San Antonio, Texas, m March, 1983. Supported by the McGregor Allergy Clinic, Houston, Texas. MARVIN S. LEGATOR GLENN KLINE V. M. SADAGOPA RAMANUJAM BRUCE R. CUNNINGHAM JONATHAN B. WARD, JR MOHY M. GAD-EL KARIM

PY - 1983/10/15

Y1 - 1983/10/15

UR - http://www.scopus.com/inward/record.url?scp=0020637566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020637566&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(83)90901-7

DO - 10.1016/S0140-6736(83)90901-7

M3 - Letter

C2 - 6137727

AN - SCOPUS:0020637566

SN - 0140-6736

VL - 322

SP - 915

JO - The Lancet

JF - The Lancet

IS - 8355

ER -

AFLATOXIN B1 IN MOULD EXTRACTS USED FOR DESENSITISATION

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

AFLATOXIN B₁ IN MOULD EXTRACTS USED FOR DESENSITISATION